{
    "symbol": "GRCL",
    "quarter": 4,
    "year": 2022,
    "date": "2023-03-13 12:03:10",
    "content": " In the U.S., we plan to initiate a company's sponsored Phase Ib and II clinical trial, evaluating GC012F for the treatment of relapsed and refractory multiple myeloma during the second quarter of 2023. So our data is among the first to demonstrate the material benefits CAR-T can bring to the newly diagnosed multiple myeloma patients, including shortening the diagnosis to treatment time, deepening the response and maximizing the response rate or achieved with a good safety profile."
}